Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Legal Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,003 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 17,557 · Balance 61,003 F1: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2022 Filed May 4, 2022 16:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,347 | $80.38 | $1,233,591.86 |
DisclosureSEC source: 0001567619-22-009494 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,339 F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 4, 2022. Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,347 | $37.46 | $574,898.62 |
DisclosureSEC source: 0001567619-22-009494 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 4, 2022. Read SEC document |
| April 29, 2022 Filed May 4, 2022 16:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 341 | $62.41 | $21,280.79 |
DisclosureSEC source: 0001567619-22-009494 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,339 F1 · date: Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 25, 2022 Filed Apr 28, 2022 00:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,669 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-009054 · doc1.xml · derivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,669 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 25, 2022 Filed Apr 28, 2022 00:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,669 | $37.46 | $99,980.74 |
DisclosureSEC source: 0001567619-22-009054 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2022 Filed Mar 24, 2022 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,129 | $81.29 | $498,226.41 |
DisclosureSEC source: 0001567619-22-007415 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,329 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 4, 2022. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 01:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,252 | $80.72 | $101,061.44 |
DisclosureSEC source: 0001567619-22-007181 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,458 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 26,520 | $0.00 Strike: $78.27 | $0.00 |
DisclosureSEC source: 0001567619-22-007181 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,520 Underlying: Common Stock · 26,520 shares Expires 2032-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2023 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 8,290 | $78.27 | $648,858.30 |
DisclosureSEC source: 0001567619-22-007181 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,710 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007181 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 F1 · price: Restricted stock units granted on March 15, 2022. Price not applicable. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006716 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,960 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return for 2019 through 2021 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 100% vests on March 15, 2022, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,518 | $76.69 | $423,175.42 |
DisclosureSEC source: 0001567619-21-014415 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,590 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 12, 2021. Read SEC document |
| May 03, 2021 Filed May 5, 2021 00:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,089 | $78.30 | $163,568.70 |
DisclosureSEC source: 0001567619-21-009021 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,108 F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 12, 2021. Read SEC document |
| May 03, 2021 Filed May 5, 2021 00:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,584 | $78.30 | $202,327.20 |
DisclosureSEC source: 0001567619-21-009021 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,197 F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 12, 2021. Read SEC document |
| April 30, 2021 Filed May 5, 2021 00:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 341 | $62.41 | $21,280.79 |
DisclosureSEC source: 0001567619-21-009021 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,781 F1 · date: Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 01:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,709 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001567619-21-008381 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,709 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 12, 2021. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 01:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,709 | $79.58 | $215,582.22 |
DisclosureSEC source: 0001567619-21-008381 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,440 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 12, 2021. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 01:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,709 | $26.49 | $71,761.41 |
DisclosureSEC source: 0001567619-21-008381 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 12, 2021. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,391 | $78.52 | $109,221.32 |
DisclosureSEC source: 0001567619-21-006818 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,440 Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 01:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,252 | $77.21 | $96,666.92 |
DisclosureSEC source: 0001567619-21-006553 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,831 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 25,650 | $0.00 Strike: $78.39 | $0.00 |
DisclosureSEC source: 0001567619-21-006553 · doc1.xml · derivative · entry 4 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,650 Underlying: Common Stock · 25,650 shares Expires 2031-03-14 F2 · date: Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 5,014 | $78.39 | $393,047.46 |
DisclosureSEC source: 0001567619-21-006553 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,083 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-006553 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,097 F1 · price: Restricted stock units granted on March 15, 2021. Price not applicable. Read SEC document |
| May 01, 2020 Filed May 5, 2020 01:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 12,504 | $89.38 | $1,117,607.52 |
DisclosureSEC source: 0001567619-20-008957 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,677 F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 27, 2020. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 339 | $62.59 | $21,216.65 |
DisclosureSEC source: 0001567619-20-008957 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,181 F1 · date: Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 00:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,309 | $73.05 | $241,722.45 |
DisclosureSEC source: 0001567619-20-006970 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,842 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 28,790 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001567619-20-006634 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,790 Underlying: Common Stock · 28,790 shares Expires 2030-03-15 F2 · date: Option grant vests 12/48th on March 16, 2021 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006634 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,151 F1 · price: Restricted stock units granted on March 16, 2020. Price not applicable. Read SEC document |
| March 13, 2020 Filed Mar 18, 2020 01:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,244 | $84.50 | $612,118.00 |
DisclosureSEC source: 0001567619-20-006634 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,051 Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 02:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005679 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,295 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2019 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2020, 2021 and 2022, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 23:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,190 | $79.66 | $254,115.40 |
DisclosureSEC source: 0001567619-19-022384 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,709 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 12, 2019. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 23:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013107 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,899 F2 · date: On June 5, 2019 the reporting person gifted 300 shares to an educational institution. Read SEC document |
| April 30, 2019 Filed Jun 7, 2019 23:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001567619-19-013107 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,199 F1 · date: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 00:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,363 | $87.86 | $295,473.18 |
DisclosureSEC source: 0001567619-19-007680 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,890 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 5, 2019. Read SEC document |
| March 22, 2019 Filed Mar 27, 2019 00:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,309 | $88.05 | $291,357.45 |
DisclosureSEC source: 0001567619-19-007680 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,253 Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 21:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,907 | $93.92 | $742,625.44 |
DisclosureSEC source: 0001567619-19-007384 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,562 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 5, 2019. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 23,450 | $0.00 Strike: $94.53 | $0.00 |
DisclosureSEC source: 0001567619-19-007249 · doc1.xml · derivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,450 Underlying: Common Stock · 23,450 shares Expires 2029-03-14 F2 · date: Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007249 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,469 F1 · price: Restricted stock units granted on March 15, 2019. Price not applicable. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 6,648 | $94.53 | $628,435.44 |
DisclosureSEC source: 0001567619-19-007249 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,099 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 840 | $94.76 | $79,598.40 |
DisclosureSEC source: 0001567619-19-006236 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,747 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-006236 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,587 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 20:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 616 | $99.46 | $61,264.90 |
DisclosureSEC source: 0001567619-18-002824 · doc1.xml · nonDerivative · entry 3 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,734 Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 20:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 200 | $99.46 | $19,891.00 |
DisclosureSEC source: 0001567619-18-002824 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,350 Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 20:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,400 | $99.45 | $139,230.00 |
DisclosureSEC source: 0001567619-18-002824 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,550 Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 22:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 12,000 | $99.57 | $1,194,840.00 |
DisclosureSEC source: 0001567619-18-002760 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,950 F1 · kind: The reporting person contributed shares of common stock of BioMarin Pharmaceutical Inc. (the "Common Stock") to an exchange fund in exchange for shares of the exchange fund. The Common Stock was valued at $99.57 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed shares of common stock of BioMarin Pharmaceutical Inc. (the "Common Stock") to an exchange fund in exchange for shares of the exchange fund. The Common Stock was valued at $99.57 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,414 | $92.07 | $130,186.98 |
DisclosureSEC source: 0001140361-18-027607 · doc1.xml · nonDerivative · entry 2 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,950 Read SEC document |
| April 30, 2018 Filed Jun 7, 2018 00:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001140361-18-027607 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,364 F1 · date: Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan. F2 · balance_after: Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 79 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 13 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 22:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,350 | $81.35 | $272,522.50 |
DisclosureSEC source: 0001140361-18-015281 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,989 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 9, 2017. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 23:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,295 | $81.36 | $268,081.20 |
DisclosureSEC source: 0001140361-18-015071 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,339 Read SEC document |
| March 22, 2018 Filed Apr 27, 2018 23:11 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,308 | $81.36 | $269,138.88 |
DisclosureSEC source: 0001140361-18-020293 · doc1.xml · nonDerivative · entry 1 Davis George Eric · CIK 0001380710 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,326 F1 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of shares reported as forfeited. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.